{"disease": "colon cancer", "drug": "5-Fluorouracil", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": []}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "colon cancer", "drug": "AZD4785", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Adagrasib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Specific inhibitor to KRAS(G12C) induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy. [https://pubmed.ncbi.nlm.nih.gov/40707131/]"]}}
{"disease": "colon cancer", "drug": "Apitolisib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Aspirin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Vitamin C and D do not increase the chemopreventive effect of aspirin on colon carcinogenesis in a mouse model. [https://pubmed.ncbi.nlm.nih.gov/40118136/]", "Study on the effect and mechanism of Lacticaseibacillus rhamnosus AFY06 on inflammation-associated colorectal cancer induced by AOM/DSS in mice. [https://pubmed.ncbi.nlm.nih.gov/38572238/]", "Andean berry (Vaccinium meridionale Swartz) juice, in combination with Aspirin, displayed antiproliferative and pro-apoptotic mechanisms in vitro while exhibiting protective effects against AOM-induced colorectal cancer in vivo. [https://pubmed.ncbi.nlm.nih.gov/35761556/]", "Aspirin's effect on kinetic parameters of cells contributes to its role in reducing incidence of advanced colorectal adenomas, shown by a multiscale computational study. [https://pubmed.ncbi.nlm.nih.gov/35416770/]", "Linsitinib and aspirin as the IGF1-R antagonists, inhibit regorafenib-resistant chemotherapy in colon cancer. [https://pubmed.ncbi.nlm.nih.gov/35197754/]", "Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum. [https://pubmed.ncbi.nlm.nih.gov/33824205/]", "Nano-peroxidase a Promising Anti-inflammatory and Antibacterial Agent Against Bacteria and Inflammation Related to Colorectal Cancer. [https://pubmed.ncbi.nlm.nih.gov/33742371/]", "Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. [https://pubmed.ncbi.nlm.nih.gov/32535107/]", "Extract of Caulis Spatholobi, a novel platelet inhibitor, efficiently suppresses metastasis of colorectal cancer by targeting tumor cell-induced platelet aggregation. [https://pubmed.ncbi.nlm.nih.gov/31918208/]", "Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter. [https://pubmed.ncbi.nlm.nih.gov/31905343/]", "HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept. [https://pubmed.ncbi.nlm.nih.gov/30968769/]", "The effect of lunasin from Indonesian soybean extract on histopatologic examination and cox-2 expression in dextran sodium sulfate-induced mice colon. [https://pubmed.ncbi.nlm.nih.gov/30697362/]", "Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro. [https://pubmed.ncbi.nlm.nih.gov/29616131/]", "Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4. [https://pubmed.ncbi.nlm.nih.gov/29308184/]", "Prostaglandin E(2)-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment. [https://pubmed.ncbi.nlm.nih.gov/29259703/]", "Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. [https://pubmed.ncbi.nlm.nih.gov/29152088/]", "The aspirin metabolite salicylate inhibits lysine acetyltransferases and MUC1 induced epithelial to mesenchymal transition. [https://pubmed.ncbi.nlm.nih.gov/28717171/]"]}}
{"disease": "colon cancer", "drug": "Belotecan", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Berberine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Berberine inhibits colorectal liver metastasis via modulation of TGF-β in a cecum transplant mouse model. [https://pubmed.ncbi.nlm.nih.gov/39558413/]", "Suppression of Berberine and Probiotics (in vitro and in vivo) on the Growth of Colon Cancer With Modulation of Gut Microbiota and Butyrate Production. [https://pubmed.ncbi.nlm.nih.gov/35572672/]", "Investigation of Molecular Mechanism of Banxia Xiexin Decoction in Colon Cancer via Network Pharmacology and In Vivo Studies. [https://pubmed.ncbi.nlm.nih.gov/35815259/]"]}}
{"disease": "colon cancer", "drug": "Bevacizumab", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation [https://clinicaltrials.gov/study/NCT06252649]", "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) [https://clinicaltrials.gov/study/NCT05239741]"]}}
{"disease": "colon cancer", "drug": "Binimetinib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Noninvasive Therapeutic Monitoring of Circulating Tumor DNA in BRAF-Mutant Metastatic Colon Cancer Using Droplet Digital PCR, Next-Generation Sequencing, and Fragmentomics. [https://pubmed.ncbi.nlm.nih.gov/41245504/]"]}}
{"disease": "colon cancer", "drug": "Capecitabine", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer [https://clinicaltrials.gov/study/NCT06368141]"]}}
{"disease": "colon cancer", "drug": "Carmofur", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["[Anti-tumor effects of carmofur on human 5-FU resistant cells]. [https://pubmed.ncbi.nlm.nih.gov/10553419/]"]}}
{"disease": "colon cancer", "drug": "Celecoxib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Camptothecin-loaded chondroitin sulfate-celecoxib reduction-sensitive micelles for enhanced colon cancer treatment. [https://pubmed.ncbi.nlm.nih.gov/40409631/]", "Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription. [https://pubmed.ncbi.nlm.nih.gov/39225209/]", "ADT-OH synergistically enhanced the antitumor activity of celecoxib in human colorectal cancer cells. [https://pubmed.ncbi.nlm.nih.gov/37492969/]", "Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer. [https://pubmed.ncbi.nlm.nih.gov/35868865/]", "Celecoxib-Loaded Solid Lipid Nanoparticles for Colon Delivery: Formulation Optimization and In Vitro Assessment of Anti-Cancer Activity. [https://pubmed.ncbi.nlm.nih.gov/35057027/]", "COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes. [https://pubmed.ncbi.nlm.nih.gov/34987061/]", "Piperine and Celecoxib synergistically inhibit colon cancer cell proliferation via modulating Wnt/β-catenin signaling pathway. [https://pubmed.ncbi.nlm.nih.gov/33667839/]", "Inhibition of COX-2 Impairs Colon Cancer Liver Metastasis through Reduced Stromal Cell Reaction. [https://pubmed.ncbi.nlm.nih.gov/33455946/]", "Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. [https://pubmed.ncbi.nlm.nih.gov/31277230/]", "Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. [https://pubmed.ncbi.nlm.nih.gov/27761963/]"]}}
{"disease": "colon cancer", "drug": "Cenegermin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Cetuximab", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": ["Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab [https://clinicaltrials.gov/study/NCT07253896]", "A Phase 3 Study of MK-1084 in Combination With Pembrolizumab Versus Standard of Care in Participants With Previously Untreated Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT06997497]", "A Phase I/Ib Study of Inavolisib in Combination With Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, and SY-5609 in Patients With Metastatic Colorectal Cancer (MCC) [https://clinicaltrials.gov/study/NCT04929223]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer. [https://pubmed.ncbi.nlm.nih.gov/39128702/]", "Targeted delivery of FAK siRNA by engineered exosomes to reverse cetuximab resistance via activating paraptosis in colon cancer. [https://pubmed.ncbi.nlm.nih.gov/38960944/]", "Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS(G12D) Inhibitor, in Colorectal Cancer Treatment. [https://pubmed.ncbi.nlm.nih.gov/37772552/]", "Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer. [https://pubmed.ncbi.nlm.nih.gov/36357605/]", "Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW. [https://pubmed.ncbi.nlm.nih.gov/35517713/]", "MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her-2/PI3K/AKT Signaling. [https://pubmed.ncbi.nlm.nih.gov/32670759/]", "Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. [https://pubmed.ncbi.nlm.nih.gov/31409052/]"]}}
{"disease": "colon cancer", "drug": "Curcumin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Curcumin Nanoparticle Induces Apoptosis in Colon Cancer Cells via ROS-Mediated AMPK/mTOR/ULK1 Autophagy Pathway. [https://pubmed.ncbi.nlm.nih.gov/41252742/]", "Synergistic anticancer efficacy of optimized curcumin-piperine loaded magnetic nanoparticles for the treatment of colorectal cancer. [https://pubmed.ncbi.nlm.nih.gov/41140878/]", "Antitumor and Immunoregulatory Effects of Curcumin Analog, (Z)-3-Hydroxy-1-(2-hydroxyphenyl)-3-phenyl prop-2-ene-1-one (DK1), on CT26-Tumor-Bearing BALB/c Mi. [https://pubmed.ncbi.nlm.nih.gov/41140209/]", "Exploration of the mechanism of curcumin in the regulation of apoptosis for the treatment of colorectal cancer. [https://pubmed.ncbi.nlm.nih.gov/40950661/]", "Chondroitin sulfate polyelectrolyte nanoparticles for Controlled Release of Dexamethasone: Improvement of the Anticancer Activity of Curcumin. [https://pubmed.ncbi.nlm.nih.gov/40513735/]", "Curcumin protects extracellular matrix to maintain microenvironmental stability inhibiting colon cancer metastasis through HPSE/IL-6/STAT5 axis. [https://pubmed.ncbi.nlm.nih.gov/40464979/]", "Synergistic Inhibition of Colon Cancer Cell Proliferation via p53, Bax, and Bcl-2 Modulation by Curcumin and Plumbagin Combination. [https://pubmed.ncbi.nlm.nih.gov/40385152/]", "Fabrication and Evaluation of Polyhydroxyalkanoate-Based Nanoparticles for Curcumin Delivery in Biomedical Applications. [https://pubmed.ncbi.nlm.nih.gov/40141993/]", "Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer. [https://pubmed.ncbi.nlm.nih.gov/40037453/]", "Anti-metastasis Effects and Mechanism of Action of Curcumin Analog (2E,6E)-2,6-bis(2,3-dimethoxybenzylidene) Cyclohexanone (DMCH) on the SW620 Colorectal Cancer Cell Line. [https://pubmed.ncbi.nlm.nih.gov/39779570/]", "Preparation and anti-colon cancer effect of a novel curcumin analogue (CA8): in vivo and in vitro evaluation. [https://pubmed.ncbi.nlm.nih.gov/39600365/]", "Post-therapy via integrated curcumin and doxorubicin modified cerium-based UiO-66 MOFs using an antioxidant and anticancer therapeutic strategy. [https://pubmed.ncbi.nlm.nih.gov/39440435/]", "Research on curcumin mediating immunotherapy of colorectal cancer by regulating cancer associated fibroblasts. [https://pubmed.ncbi.nlm.nih.gov/39264802/]", "Curcumin-shellac nanoparticle-loaded GelMA/SilMA hydrogel for colorectal cancer therapy. [https://pubmed.ncbi.nlm.nih.gov/38996942/]", "Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer. [https://pubmed.ncbi.nlm.nih.gov/38891089/]", "Advancing Gastrointestinal Health: Curcumin's Efficacy and Nanopreparations. [https://pubmed.ncbi.nlm.nih.gov/38611938/]", "Amplifying Curcumin's Antitumor Potential: A Heat-Driven Approach for Colorectal Cancer Treatment. [https://pubmed.ncbi.nlm.nih.gov/38313386/]", "Tumour-suppressive effects of curcumin analogs CCA-1.1 and Pentagamavunone-1 in colon cancer: In vivo and in vitro studies. [https://pubmed.ncbi.nlm.nih.gov/38107450/]", "Ruthenium(II)-Arene Curcuminoid Complexes as Photosensitizer Agents for Antineoplastic and Antimicrobial Photodynamic Therapy: In Vitro and In Vivo Insights. [https://pubmed.ncbi.nlm.nih.gov/38005258/]", "Folic Acid-Functionalized Albumin/Graphene Oxide Nanocomposite to Simultaneously Deliver Curcumin and 5-Fluorouracil into Human Colorectal Cancer Cells: An In Vitro Study. [https://pubmed.ncbi.nlm.nih.gov/37304465/]"]}}
{"disease": "colon cancer", "drug": "Dactolisib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Dalfampridine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Daratumumab", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread", "NCTID": "NCT02060188", "drug_for_treatment": ["Nivolumab", "Ipilimumab", "Cobimetinib", "Daratumumab", "Relatlimab"], "indication": "Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colorectal Cancer", "result_summary_sentence": "The study has available results indicating the safety and efficacy of Nivolumab and its combinations in treating recurrent and metastatic colorectal cancer.", "phase": "Phase 2", "risk_level": "Moderate", "positive_or_negative": "Positive", "population_summary": "Patients with recurrent and metastatic MSI-H and non-MSI-H colorectal cancer", "has_results": true, "sample_size": 335, "start_year": 2014, "this_year-start_year": 9, "complete_year": 2023}, "scoring": {"mechanism": {"score": 90, "explanation": "Nivolumab is a PD-1 inhibitor, which is a well-established mechanism in oncology, particularly in cancers with high mutational burden like MSI-H colorectal cancer. The mechanistic rationale is strong as PD-1 inhibition is directly linked to enhancing immune response against tumors."}, "clinical_evidence": {"score": 85, "explanation": "The study has available results showing objective responses and measurable antitumor effects in patients treated with Nivolumab and its combinations. This provides high confidence in the clinical efficacy of the drug."}, "safety_predictability": {"score": 70, "explanation": "The safety profile of Nivolumab and its combinations is consistent with known immune-related adverse events. The study reports manageable toxicities, which aligns with expectations based on the drug's mechanism."}, "trial_quality": {"score": 75, "explanation": "The trial design includes meaningful endpoints and appropriate inclusion criteria to detect clinical signals. The sample size and phase are adequate for assessing efficacy and safety."}, "result_status": {"score": 80, "category": "good", "explanation": "The study has available positive results indicating clinical efficacy and safety of Nivolumab and its combinations in the target population."}, "target_drug_importance": {"score": 90, "role": "major", "explanation": "Nivolumab is the primary experimental agent in the study, and the results are directly informative for evaluating its efficacy and safety in colorectal cancer."}, "overall_confidence": {"score": 85, "explanation": "Based on the strong mechanistic rationale, positive clinical evidence, and the importance of Nivolumab as the primary drug in the study, the overall confidence in the investigational drug is very high."}}, "nct_id": "NCT02060188"}]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Dichloroacetate", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. [https://pubmed.ncbi.nlm.nih.gov/27803917/]", "Selection of cancer cells with repressed mitochondria triggers colon cancer progression. [https://pubmed.ncbi.nlm.nih.gov/20080835/]"]}}
{"disease": "colon cancer", "drug": "Elotuzumab", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Encorafenib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Noninvasive Therapeutic Monitoring of Circulating Tumor DNA in BRAF-Mutant Metastatic Colon Cancer Using Droplet Digital PCR, Next-Generation Sequencing, and Fragmentomics. [https://pubmed.ncbi.nlm.nih.gov/41245504/]"]}}
{"disease": "colon cancer", "drug": "Epigallocatechin gallate (EGCG)", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Antitumor Effects of Epigallocatechin-3-Gallate on Colorectal Cancer: An In Vitro and In Vivo Study. [https://pubmed.ncbi.nlm.nih.gov/40578931/]", "Epigallocatechin-3-gallate suppresses hemin-aggravated colon carcinogenesis through Nrf2-inhibited mitochondrial reactive oxygen species accumulation. [https://pubmed.ncbi.nlm.nih.gov/36174978/]", "Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3-gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles. [https://pubmed.ncbi.nlm.nih.gov/31374249/]", "Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently suppresses dextran sulfate sodium-induced colitis and colon tumorigenesis in mice. [https://pubmed.ncbi.nlm.nih.gov/22409325/]"]}}
{"disease": "colon cancer", "drug": "Eribulin", "Q1": {"selection": "Completed phase I with positive result (or FDA-Approved for other diseases)", "clinicaltrial_references": ["A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer [https://clinicaltrials.gov/study/NCT01744340]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Everolimus", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Everolimus exerts anticancer effects through inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2 in colon cancer cells. [https://pubmed.ncbi.nlm.nih.gov/38314724/]", "Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. [https://pubmed.ncbi.nlm.nih.gov/18319715/]", "RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. [https://pubmed.ncbi.nlm.nih.gov/16061672/]"]}}
{"disease": "colon cancer", "drug": "Floxuridine", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver [https://clinicaltrials.gov/study/NCT03366155]", "PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma [https://clinicaltrials.gov/study/NCT05286814]", "Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer [https://clinicaltrials.gov/study/NCT00361842]"]}}
{"disease": "colon cancer", "drug": "Fluorouracil", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": ["Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation [https://clinicaltrials.gov/study/NCT06252649]", "A Study of MK-1084 in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (mCRC) (KANDLELIT-012) [https://clinicaltrials.gov/study/NCT06997497]", "Atezolizumab Plus FOLFOX in Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT02912559]"]}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Anticancer efficacy of albumin nanoparticles co-loaded with silver nanoparticles and 5FU in animal model of colon cancer. [https://pubmed.ncbi.nlm.nih.gov/41023100/]", "Chemophotothermal Combined Therapy with 5-Fluorouracil and Branched Gold Nanoshell Hyperthermia Induced a Reduction in Tumor Size in a Xenograft Colon Cancer Model. [https://pubmed.ncbi.nlm.nih.gov/40871011/]"]}}
{"disease": "colon cancer", "drug": "GSK2636771", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Gimeracil", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT06255379]", "S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery [https://clinicaltrials.gov/study/NCT00974389]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Hydroxyurea", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Antitumor mechanisms of amino Acid hydroxyurea derivatives in the metastatic colon cancer model. [https://pubmed.ncbi.nlm.nih.gov/24304540/]"]}}
{"disease": "colon cancer", "drug": "Indomethacin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Highly specific colon-targeted transformable capsules containing indomethacin immediate-release pellets for colon cancers therapy. [https://pubmed.ncbi.nlm.nih.gov/31100991/]", "The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. [https://pubmed.ncbi.nlm.nih.gov/23338686/]", "Chemoprevention with phosphatidylcholine non-steroidal anti-inflammatory drugs in vivo and in vitro. [https://pubmed.ncbi.nlm.nih.gov/29616131/]"]}}
{"disease": "colon cancer", "drug": "Irinotecan", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": []}}
{"disease": "colon cancer", "drug": "Isatuximab", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)", "NCTID": "NCT03555149", "drug_for_treatment": ["atezolizumab", "bevacizumab", "isatuximab", "selicrelumab", "RG7388"], "indication": "Metastatic Colorectal Cancer", "result_summary_sentence": "The study aimed to evaluate the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with metastatic colorectal cancer. Preliminary efficacy, safety, and PK data were obtained, but no formal statistical hypothesis testing was performed.", "phase": "Phase Ib/II", "risk_level": "Moderate", "positive_or_negative": "Mixed", "population_summary": "Patients with metastatic colorectal cancer", "has_results": true, "sample_size": 91, "start_year": 2018, "this_year-start_year": 5, "complete_year": 2023}, "scoring": {"mechanism": {"score": 75, "explanation": "The drug mechanisms, including PD-L1 inhibition (atezolizumab) and VEGF inhibition (bevacizumab), are well-established in oncology and have shown relevance in various cancers, including colorectal cancer. However, the combination with other agents like isatuximab and selicrelumab is less validated."}, "clinical_evidence": {"score": 60, "explanation": "Preliminary efficacy and safety data are available, but the study was not designed for formal hypothesis testing, and some experimental arms were terminated prematurely. This limits the strength of the clinical evidence."}, "safety_predictability": {"score": 65, "explanation": "The safety profile includes known toxicities of the involved drugs, such as hypertension and xeroderma. The study reported adverse events, but the limited sample size and early termination of some arms necessitate cautious interpretation."}, "trial_quality": {"score": 55, "explanation": "The study design aimed to gather preliminary data without formal statistical hypothesis testing. The limited sample size and early termination of some arms reduce the robustness of the trial design."}, "result_status": {"score": 49, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for more than 5 years without conclusive results, and some arms were terminated prematurely. This indicates long-term incomplete status."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "The investigational drugs are central to the study's outcome, as the trial focuses on evaluating their efficacy and safety in combination therapies for metastatic colorectal cancer."}, "overall_confidence": {"score": 60, "explanation": "The overall confidence is moderate due to the mixed preliminary results, the relevance of the drug mechanisms, and the limitations in trial design and sample size. The long-term incomplete status further impacts the confidence level."}}, "nct_id": "NCT03555149"}]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Melatonin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Targeted colon cancer therapy using lapatinib-encapsulated chitosan nanoparticles conjugated with lactoferrin and melatonin with integrated in silico in vitro and in vivo evaluation. [https://pubmed.ncbi.nlm.nih.gov/41186110/]", "Fabrication of lactoferrin-chitosan-etoposide nanoparticles with melatonin via carbodiimide coupling: In-vitro & in-vivo evaluation for colon cancer. [https://pubmed.ncbi.nlm.nih.gov/39637989/]", "Hyaluronic acid-functionalized carboxymethyl dextran-coated melatonin nanoconjugates for targeted etoposide delivery in metastatic colon cancer: Extensive in-vitro investigation in HCT116 cell lines, antimicrobial efficacy, and anti-angiogenic potential in chick chorioallantoic membrane (CAM) assay. [https://pubmed.ncbi.nlm.nih.gov/39395515/]", "Combinatorial effects of melatonin and paclitaxel differ depending on the treatment scheme in colorectal cancer in vitro. [https://pubmed.ncbi.nlm.nih.gov/36063977/]", "Melatonin inhibits proliferation and viability and promotes apoptosis in colorectal cancer cells via upregulation of the microRNA-34a/449a cluster. [https://pubmed.ncbi.nlm.nih.gov/33398374/]", "Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. [https://pubmed.ncbi.nlm.nih.gov/28819759/]", "The Impact of Melatonin on Colon Cancer Cells' Resistance to Doxorubicin in an in Vitro Study. [https://pubmed.ncbi.nlm.nih.gov/28788434/]", "Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. [https://pubmed.ncbi.nlm.nih.gov/27865009/]", "Melatonin inhibits the Migration of Colon Cancer RKO cells by Down-regulating Myosin Light Chain Kinase Expression through Cross-talk with p38 MAPK. [https://pubmed.ncbi.nlm.nih.gov/26320459/]", "Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line. [https://pubmed.ncbi.nlm.nih.gov/25873273/]"]}}
{"disease": "colon cancer", "drug": "Melphalan", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease [https://clinicaltrials.gov/study/NCT06607458]", "Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver [https://clinicaltrials.gov/study/NCT00019760]"]}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo. [https://pubmed.ncbi.nlm.nih.gov/15081876/]", "Enhancement of melphalan (L-PAM) toxicity by reductive metabolites of 1-methyl-2-nitroimidazole, a model nitroimidazole chemosensitizing agent. [https://pubmed.ncbi.nlm.nih.gov/2260990/]"]}}
{"disease": "colon cancer", "drug": "Nifurtimox", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Nivolumab", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT04017650]", "NCI-2015-00054 [https://clinicaltrials.gov/study/NCT02465060]", "Testing the Addition of Encorafenib and Cetuximab to Nivolumab in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT05308446]"]}}
{"disease": "colon cancer", "drug": "Omega-3 Fatty Acids", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. [https://pubmed.ncbi.nlm.nih.gov/25773851/]", "Down-regulation of malignant potential by alpha linolenic acid in human and mouse colon cancer cells. [https://pubmed.ncbi.nlm.nih.gov/25336096/]"]}}
{"disease": "colon cancer", "drug": "Oteracil", "Q1": {"selection": "In phase II", "clinicaltrial_references": ["Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer [https://clinicaltrials.gov/study/NCT06255379]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Oxaliplatin", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": []}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "colon cancer", "drug": "Panitumumab", "Q1": {"selection": "In phase III", "clinicaltrial_references": ["Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation [https://clinicaltrials.gov/study/NCT05198934]", "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation [https://clinicaltrials.gov/study/NCT06252649]", "Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and a Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver [https://clinicaltrials.gov/study/NCT02885753]"]}}
{"disease": "colon cancer", "drug": "Plerixafor", "Q1": {"selection": "In phase I", "clinicaltrial_references": ["To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers [https://clinicaltrials.gov/study/NCT02179970]"]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Plicamycin", "Q1": {"selection": "No", "clinicaltrial_references": [{"study_summary": {"title": "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases", "NCTID": "NCT02859415", "drug_for_treatment": ["Mithramycin"], "indication": "Primary thoracic malignancies or carcinomas, sarcomas or germ cell neoplasms with pleuropulmonary metastases", "result_summary_sentence": "The study has available results indicating some adverse events but lacks detailed efficacy data.", "phase": "Phase I/II", "risk_level": "High", "positive_or_negative": "Neutral", "population_summary": "Patients with primary thoracic malignancies or carcinomas, sarcomas or germ cell neoplasms with pleuropulmonary metastases", "has_results": true, "sample_size": 3, "start_year": 2016, "this_year-start_year": 7, "complete_year": 2022}, "scoring": {"mechanism": {"score": 75, "explanation": "Mithramycin targets cancer stem cell signaling, which is a relevant mechanism in thoracic malignancies and metastases. However, while the target is known to be relevant, similar mechanisms have had mixed success in clinical settings."}, "clinical_evidence": {"score": 40, "explanation": "The study has available results, but they primarily report adverse events without detailed efficacy data. This limits the strength of clinical evidence."}, "safety_predictability": {"score": 50, "explanation": "The study reports several adverse events, including bronchopulmonary hemorrhage and hypoalbuminemia. These events are consistent with the known toxicities of Mithramycin, indicating predictable safety concerns."}, "trial_quality": {"score": 60, "explanation": "The trial design includes continuous 24h intravenous infusion, which is appropriate for evaluating the drug's efficacy and safety. However, the small sample size limits the robustness of the findings."}, "result_status": {"score": 45, "category": "ongoing_long_term_incomplete", "explanation": "The study has been ongoing for more than 7 years, which exceeds normal development timelines for Phase I/II trials. Although results are available, they are incomplete regarding efficacy."}, "target_drug_importance": {"score": 80, "role": "major", "explanation": "Mithramycin is the primary experimental agent in this study, making its evaluation central to the study outcome."}, "overall_confidence": {"score": 55, "explanation": "Moderate confidence in Mithramycin's potential efficacy against thoracic malignancies and metastases. The mechanistic rationale is strong, but clinical evidence is limited and safety concerns are significant."}}, "nct_id": "NCT02859415"}]}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Ramucirumab", "Q1": {"selection": "Completed phase II with positive result", "clinicaltrial_references": ["A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer [https://clinicaltrials.gov/study/NCT00862784]", "A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) [https://clinicaltrials.gov/study/NCT01286818]"]}, "Q2": {"selection": "", "literature_references": []}}
{"disease": "colon cancer", "drug": "Regorafenib", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": ["QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy [https://clinicaltrials.gov/study/NCT03167177]", "Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation [https://clinicaltrials.gov/study/NCT05198934]", "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer [https://clinicaltrials.gov/study/NCT05600309]", "Akkermansia Probiotics and Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer [https://clinicaltrials.gov/study/NCT06865521]"]}}
{"disease": "colon cancer", "drug": "Resveratrol", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Mechanism of Resveratrol on LPS/ATP-induced pyroptosis and inflammatory response in HT29 cells. [https://pubmed.ncbi.nlm.nih.gov/39534992/]", "Genotoxic and Anti-Migratory Effects of Camptothecin Combined with Celastrol or Resveratrol in Metastatic and Stem-like Cells of Colon Cancer. [https://pubmed.ncbi.nlm.nih.gov/39409900/]", "Inhibitory effects of resveratrol on platelet activation and thrombosis in colon cancer through regulation of the MAPK and cGMP/VASP pathways. [https://pubmed.ncbi.nlm.nih.gov/39098189/]", "pH-responsive resveratrol-loaded ZIF-8 nanoparticles modified with tannic acid for promoting colon cancer cell apoptosis. [https://pubmed.ncbi.nlm.nih.gov/37702969/]", "Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment. [https://pubmed.ncbi.nlm.nih.gov/36382309/]", "Proapoptotic Effect and Molecular Docking Analysis of Curcumin-Resveratrol Hybrids in Colorectal Cancer Chemoprevention. [https://pubmed.ncbi.nlm.nih.gov/35684424/]", "In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer. [https://pubmed.ncbi.nlm.nih.gov/33965502/]"]}}
{"disease": "colon cancer", "drug": "Salirasib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": ["Continuous treatment with FTS confers resistance to apoptosis and affects autophagy. [https://pubmed.ncbi.nlm.nih.gov/28151959/]", "Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. [https://pubmed.ncbi.nlm.nih.gov/25261371/]"]}}
{"disease": "colon cancer", "drug": "Sotorasib", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Specific inhibitor to KRAS(G12C) induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy. [https://pubmed.ncbi.nlm.nih.gov/40707131/]"]}}
{"disease": "colon cancer", "drug": "Sulforaphane", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Sulforaphane Attenuates AOM/DSS-Induced Colorectal Tumorigenesis in Mice via Inhibition of Intestinal Inflammation. [https://pubmed.ncbi.nlm.nih.gov/37897077/]"]}}
{"disease": "colon cancer", "drug": "Tagraxofusp", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"raw_text": "```json\n{\n  \"disease\": \"colon cancer\",\n  \"drug\": \"Talaporfin\",\n  \"Q1\": {\n    \"selection\": \"No\",\n    \"clinicaltrial_references\": [\n      {\n        \"study_summary\": {\n          \"title\": \"Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases\",\n          \"NCTID\": \"NCT00440310\",\n          \"drug_for_treatment\": [\"Litx™\", \"Chemotherapy\"],\n          \"indication\": \"Colorectal Cancer with Recurrent Liver Metastases\",\n          \"result_summary_sentence\": \"The study evaluated the safety and efficacy of Litx™ plus chemotherapy compared to chemotherapy alone in treating colorectal cancer patients with recurrent liver metastases.\",\n          \"phase\": \"Phase 3\",\n          \"risk_level\": \"High\",\n          \"positive_or_negative\": \"Negative\",\n          \"population_summary\": \"Colorectal cancer patients with recurrent liver metastases\",\n          \"has_results\": true,\n          \"sample_size\": 454,\n          \"start_year\": 2007,\n          \"this_year-start_year\": 16,\n          \"complete_year\": 2010\n        },\n        \"scoring\": {\n          \"mechanism\": {\n            \"score\": 60,\n            \"explanation\": \"The mechanistic rationale for Litx™ involves photodynamic therapy, which is a known approach in oncology. However, its specific application to colorectal cancer with liver metastases is less established compared to other mechanisms like targeted therapies or immunotherapies.\"\n          },\n          \"clinical_evidence\": {\n            \"score\": 30,\n            \"explanation\": \"The study has been completed for over 12 years, and the results indicate no significant improvement in efficacy with the addition of Litx™ to chemotherapy. This weakens the clinical evidence supporting the investigational drug.\"\n          },\n          \"safety_predictability\": {\n            \"score\": 50,\n            \"explanation\": \"The safety profile of Litx™ combined with chemotherapy shows some expected toxicities, but the overall safety and tolerability are within acceptable ranges for oncology treatments. However, the addition of Litx™ did not significantly improve outcomes.\"\n          },\n          \"trial_quality\": {\n            \"score\": 70,\n            \"explanation\": \"The trial design is robust, being a multicenter, multinational, randomized Phase 3 study. The endpoints and inclusion criteria are appropriate for detecting meaningful signals in this patient population.\"\n          },\n          \"result_status\": {\n            \"score\": 10,\n            \"category\": \"bad\",\n            \"explanation\": \"The study results are available and indicate that the addition of Litx™ to chemotherapy did not provide a significant benefit over chemotherapy alone, leading to a negative outcome.\"\n          },\n          \"target_drug_importance\": {\n            \"score\": 80,\n            \"role\": \"major\",\n            \"explanation\": \"Litx™ is the primary experimental agent in this study, and its efficacy and safety are central to the study's outcome. The results directly inform the evaluation of Litx™ in this indication.\"\n          },\n          \"overall_confidence\": {\n            \"score\": 35,\n            \"explanation\": \"Given the negative results from a well-designed Phase 3 trial, the overall confidence in Litx™ for treating colorectal cancer with recurrent liver metastases is low. The mechanistic rationale and safety profile are not sufficient to overcome the lack of clinical efficacy.\"\n        }\n      },\n      \"nct_id\": \"NCT00440310\"\n    },\n    {\n      \"study_summary\": {\n        \"title\": \"Study of the Litx™ System Combined With Chemotherapy in Patients With Colorectal Liver Metastases\",\n        \"NCTID\": \"NCT00083785\",\n        \"drug_for_treatment\": [\"Talaporfin sodium (LS11)\"],\n        \"indication\": \"Liver Metastasis from Colorectal Cancer\",\n        \"result_summary_sentence\": \"No results have been posted for this study.\",\n        \"phase\": \"PHASE2\",\n        \"risk_level\": \"Moderate\",\n        \"positive_or_negative\": \"Neutral\",\n        \"population_summary\": \"Patients with metastatic liver lesions from colorectal disease, aged 18 years and older, with 4 or fewer lesions greater than 1 cm and no single lesion greater than 7 cm in maximum diameter.\",\n        \"has_results\": false,\n        \"sample_size\": 25,\n        \"start_year\": 2004,\n        \"this_year-start_year\": 19,\n        \"complete_year\": null\n      },\n      \"scoring\": {\n        \"mechanism\": {\n          \"score\": 75,\n          \"explanation\": \"Talaporfin sodium (LS11) is a photosensitizer used in photodynamic therapy (PDT). The mechanism involves activation by light to produce reactive oxygen species that induce cell death. This mechanism is relevant to the biology of cancer, particu\"\n        },\n        \"clinical_evidence\": {\n          \"score\": 30,\n          \"explanation\": \"The study is in Phase II and has been ongoing for a significant period without posted results. This lack of available clinical data weakens the confidence in the early clinical signals.\"\n        },\n        \"safety_predictability\": {\n          \"score\": 50,\n          \"explanation\": \"Based on the mechanism of action, expected toxicities include photosensitivity and potential liver-related adverse events. The safety profile is moderately predictable, but detailed safety data from this study are not available.\"\n        },\n        \"trial_quality\": {\n          \"score\": 60,\n          \"explanation\": \"The trial design includes a non-randomized, single-group assignment, which may limit the robustness of the efficacy signals. However, the inclusion criteria are well-defined, and the endpoints are appropriate for a Phase II study.\"\n        },\n        \"result_status\": {\n          \"score\": 40,\n          \"category\": \"ongoing_long_term_incomplete\",\n          \"explanation\": \"The study has been ongoing for 19 years without posted results, which exceeds normal development timelines for Phase II trials. This significantly impacts the confidence in the investigational drug.\"\n        },\n        \"target_drug_importance\": {\n          \"score\": 80,\n          \"role\": \"major\",\n          \"explanation\": \"Talaporfin sodium (LS11) is the primary experimental agent in this study, making its individual contribution central to the study outcome.\"\n        },\n        \"overall_confidence\": {\n          \"score\": 55,\n          \"explanation\": \"While the mechanistic rationale and target drug importance are strong, the lack of clinical evidence and long-term incomplete status of the study reduce overall confidence in the investigational drug.\"\n      }\n    },\n    \"nct_id\": \"NCT00083785\"\n  },\n  {\n    \"study_summary\": {\n      \"title\": \"Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases\",\n      \"NCTID\": \"NCT00068068\",\n      \"drug_for_treatment\": [\"Talaporfin sodium (LS11)\"],\n      \"indication\": \"Liver Metastasis from Colorectal Cancer\",\n      \"result_summary_sentence\": \"The study aims to evaluate the safety and efficacy of Talaporfin sodium (LS11) in treating patients with liver metastases from colorectal cancer that have failed chemotherapy.\",\n      \"phase\": \"PHASE2\",\n      \"risk_level\": \"Moderate\",\n      \"positive_or_negative\": \"\",\n      \"population_summary\": \"Patients with metastatic liver lesions from colorectal disease who have failed or progressed on a chemotherapy regimen for metastatic disease.\",\n      \"has_results\": false,\n      \"sample_size\": 25,\n      \"start_year\": 2003,\n      \"this_year-start_year\": 20,\n      \"complete_year\": null\n    },\n    \"scoring\": {\n      \"mechanism\": {\n        \"score\": 70,\n        \"explanation\": \"Talaporfin sodium (LS11) is a photosensitizer used in photodynamic therapy, which is a well-established mechanism for targeting cancer cells. The mechanism is relevant to the disease biology as it aims to ablate tumor cells in the liver metastases. However, the success of similar mechanisms in this specific indication is limited.\"\n      },\n      \"clinical_evidence\": {\n        \"score\": 30,\n        \"explanation\": \"The study is in Phase II and has been ongoing for a significant period without posted results. This lack of available clinical data weakens the confidence in the early clinical signals.\"\n      },\n      \"safety_predictability\": {\n        \"score\": 50,\n        \"explanation\": \"Based on the mechanism of action, expected toxicities include photosensitivity and potential liver-related adverse events. The safety profile is moderately predictable, but detailed safety data from this study are not available.\"\n      },\n      \"trial_quality\": {\n        \"score\": 60,\n        \"explanation\": \"The trial design includes a non-randomized, single-group assignment, which may limit the robustness of the efficacy signals. However, the inclusion criteria are well-defined, and the endpoints are appropriate for a Phase II study.\"\n      },\n      \"result_status\": {\n        \"score\": 40,\n        \"category\": \"ongoing_long_term_incomplete\",\n        \"explanation\": \"The study has been ongoing for 20 years without posted results, which exceeds normal development timelines for a Phase II trial. This long-term incompleteness significantly impacts the confidence in the study outcomes.\"\n      },\n      \"target_drug_importance\": {\n        \"score\": 80,\n        \"role\": \"major\",\n        \"explanation\": \"Talaporfin sodium (LS11) is the primary experimental agent in this study, making its evaluation central to the study outcomes.\"\n      },\n      \"overall_confidence\": {\n       ", "disease": "colon cancer", "drug": "Talaporfin"}
{"disease": "colon cancer", "drug": "Talimogene laherparepvec", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Tegafur", "Q1": {"selection": "Completed phase III with positive result", "clinicaltrial_references": ["A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC) [https://clinicaltrials.gov/study/NCT00152230]"]}, "Q2": {"selection": "Positive result in vivo result", "literature_references": ["Oral administration of uracil-tegafur (UFT) inhibits liver micrometastasis of human colon cancer in an orthotopic nude mouse model and its early detection system. [https://pubmed.ncbi.nlm.nih.gov/15449156/]", "Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. [https://pubmed.ncbi.nlm.nih.gov/22870097/]"]}}
{"disease": "colon cancer", "drug": "Teriflunomide", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in vitro result", "literature_references": ["Teriflunomide - The common drug with underestimated oxygen - Dependent anticancer potential. [https://pubmed.ncbi.nlm.nih.gov/34611552/]"]}}
{"disease": "colon cancer", "drug": "Tipiracil", "Q1": {"selection": "FDA-Approved to colon cancer", "clinicaltrial_references": ["TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study [https://clinicaltrials.gov/study/NCT04109924]", "TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy [https://clinicaltrials.gov/study/NCT05343013]"]}}
{"disease": "colon cancer", "drug": "Tretamine", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "TrifluridineO", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Valrubicin", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Rarely discussed", "literature_references": []}}
{"disease": "colon cancer", "drug": "Vitamin D", "Q1": {"selection": "No", "clinicaltrial_references": []}, "Q2": {"selection": "Positive result in animal study", "literature_references": ["Vitamin C and D do not increase the chemopreventive effect of aspirin on colon carcinogenesis in a mouse model. [https://pubmed.ncbi.nlm.nih.gov/40118136/]", "Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice. [https://pubmed.ncbi.nlm.nih.gov/37478851/]", "Effect of Chronic Vitamin D Deficiency on the Development and Severity of DSS-Induced Colon Cancer in Smad3(-/-) Mice. [https://pubmed.ncbi.nlm.nih.gov/32014085/]", "Losartan and Vitamin D Inhibit Colonic Tumor Development in a Conditional Apc-Deleted Mouse Model of Sporadic Colon Cancer. [https://pubmed.ncbi.nlm.nih.gov/31088824/]"]}}
